Sutton Wealth Advisors’s Amedisys AMED Stock Holding History

Sutton Wealth Advisors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8	Closed	-$774	–	1659
2022 Q3	$774	Hold	8	–	–	﹤0.01%	1364
2022 Q2	$841	Sell	8 -7	-47%	-$894	﹤0.01%	1334
2022 Q1	$2.58K	Buy	15 +3	+25%	+$448	﹤0.01%	1170
2021 Q4	$1.94K	Buy	+12	New	+$1.93K	﹤0.01%	1204
2019 Q1	–	Sell	-479	Closed	-$56.1K	–	1171
2018 Q4	$56.1K	Hold	479	–	–	0.04%	257
2018 Q3	$59.9K	Hold	479	–	–	0.04%	256
2018 Q2	$40.9K	Hold	479	–	–	0.03%	339
2018 Q1	$28.9K	Hold	479	–	–	0.02%	432
2017 Q4	$25.2K	Hold	479	–	–	0.02%	471
2017 Q3	$26.8K	Hold	479	–	–	0.02%	444
2017 Q2	$30.1K	Hold	479	–	–	0.02%	397
2017 Q1	$24.5K	Hold	479	–	–	0.02%	439
2016 Q4	$20.4K	Hold	479	–	–	0.02%	488
2016 Q3	$22.7K	Hold	479	–	–	0.02%	433
2016 Q2	$24.2K	Hold	479	–	–	0.02%	396
2016 Q1	$23.2K	Buy	+479	New	+$18.5K	0.02%	398

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sutton Wealth Advisors's AMED Position: Q4 2022 in Review

Sutton Wealth Advisors sold out of Amedisys (AMED) in Q4 2022, closing a stake of 8 shares — an estimated $774 sold.

Sutton Wealth Advisors first reported a position in AMED in Q1 2016 and held it in 16 quarters. The position peaked at $59.9K in Q3 2018. 277 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

Sutton Wealth Advisors reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
Sutton Wealth Advisors sold 8 Amedisys shares in Q4 2022, an estimated $774.
Sutton Wealth Advisors first reported a position in Amedisys in Q1 2016 and held it in 16 quarters.
Sutton Wealth Advisors's Amedisys position peaked at $59.9K in Q3 2018.
277 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on Sutton Wealth Advisors's 13F filing for Q4 2022, filed 7 Nov 2023.